(Q41101944)

26 September 2017

1 reference

title

Dapsone in rheumatoid arthritis (English)

1 reference

26 September 2017

1 reference

Chang DJ

1

1 reference

26 September 2017

Lamothe M

series ordinal

2

1 reference

26 September 2017

Stevens RM

series ordinal

3

1 reference

26 September 2017

Sigal LH

series ordinal

4

1 reference

26 September 2017

publication date

1 June 1996

1 reference

Seminars in Arthritis and Rheumatism

26 September 2017

published in

1 reference

26 September 2017

volume

25

1 reference

26 September 2017

issue

6

1 reference

26 September 2017

page(s)

390-403

1 reference

Oral therapy for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A controlled trial of trimethoprim-sulfamethoxazole versus trimethoprim-dapsone

26 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Intermittent trimethoprim-sulfamethoxazole compared with dapsone-pyrimethamine for the simultaneous primary prophylaxis of Pneumocystis pneumonia and toxoplasmosis in patients infected with HIV

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Dermatitis herpetiformis. Clinical, histologic, therapeutic and laboratory clues

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

"Sulfoxone (Diasone) sodium for dermatitis herpetiformis" by Cornbleet, December 1951. Commentary: Sulfoxone (Diasone) in the treatment of dermatitis herpetiformis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Urticaria-like lesions associated with systemic lupus erythematosus: response to dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Dapsone in the treatment of lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Review: Treatment of Cutaneous Lupus Erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Hypocomplementemic urticarial vasculitis syndrome responsive to dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Treatment of vasculitis with chlorpromazine and dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Sulfone therapy in the treatment of leukocytoclastic vasculitis. Report of three cases

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Dapsone and rheumatoid vasculitis leg ulcerations

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Dapsone in allergic vasculitis: its use in Henoch-Schönlein disease following vaccination

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Relapsing polychondritis treated with dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Treatment of relapsing polychondritis with dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Dapsone in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Effects of gold, dapsone, and prednisone on serum C-reactive protein and haptoglobin and the erythrocyte sedimentation rate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Rheumatoid arthritis: treatment which controls the C-reactive protein and erythrocyte sedimentation rate reduces radiological progression

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Double-blind trial of dapsone against placebo in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Report on chloroquine and dapsone in the treatment of rheumatoid arthritis: a 6-month comparative study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

A double-blind comparative study of hydroxychloroquine and dapsone, alone and in combination, in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Subcorneal Pustular Dermatosis and Crippling Arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Subcorneal pustular dermatosis associated with rheumatoid arthritis and raised IgA: simultaneous remission of skin and joint involvements with dapsone treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Inhibition of lysosomal enzymes by dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Anti-inflammatory actions of dapsone and its related biochemistry

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

The inhibition of polymorphonuclear leukocyte cytotoxicity by dapsone. A possible mechanism in the treatment of dermatitis herpetiformis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

In vitro and in vivo effects of dapsone on neutrophil and lymphocyte functions in normal individuals and patients with lepromatous leprosy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Dermatitis herpetiformis: Effects of sulfones and sulfonamides on neutrophil myeloperoxidase-mediated iodination and cytotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Mechanisms by which clofazimine and dapsone inhibit the myeloperoxidase system. A possible correlation with their anti-inflammatory properties

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Mechanism of inhibition of myeloperoxidase by anti-inflammatory drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Dissociation of the inhibitory effect of dapsone on the generation of oxygen intermediates—in comparision with that of colchicine and various scavengers

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Reduction of neutrophil-mediated injury to pulmonary endothelial cells by dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Effects of potassium iodide, colchicine and dapsone on the generation of polymorphonuclear leukocyte-derived oxygen intermediates

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Dapsone inhibits LTB4 binding and bioresponse at the cellular and physiologic levels

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Dapsone Suppresses Integrin-Mediated Neutrophil Adherence Function

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Inhibition of rat mast cell arachidonic acid cyclooxygenase by dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Effect of sulfones on complement deposition in dermatitis herpetiformis and on complement-mediated guinea-pig reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

The Pathogenesis of Dermatitis Herpetiformis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Adverse effects of dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Dapsone: modes of action, toxicity and possible strategies for increasing patient tolerance

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Sulfonamides and sulfones in dermatologic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

The incidence of agranulocytosis during treatment of dermatitis herpetiformis with dapsone as reported in Sweden, 1972 through 1988.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Agranulocytosis Due to Dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Agranulocytosis associated with malaria prophylaxis with Maloprim.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Leucopenia in rheumatoid arthritis: relationship to gold or sulphasalazine therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Leucopenia during sulphasalazine treatment for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Sulphasalazine in rheumatoid arthritis: haematological problems and changes in haematological indices associated with therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Psychiatric reaction to dapsone and sulfapyridine

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Manic depression induced by dapsone in patient with dermatitis herpetiformis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Drug Reactions to the Sulfones

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Dapsone and severe hypoalbuminaemia. A report of two cases

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Dapsone and severe hypoalbuminaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Dapsone and severe hypoalbuminaemia in dermatitis herpetiformis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Fatal Reaction to Dapsone During Treatment of Leprosy

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Carcinogenicity of dapsone of mice and rats.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Outcome of attempts to treat rheumatoid arthritis with gold, penicillamine, sulphasalazine, or dapsone

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Dapsone in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Dapsone—Other Indications

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

The use of cimetidine as a selective inhibitor of dapsone N-hydroxylation in man.

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

The use of cimetidine to reduce dapsone-dependent methaemoglobinaemia in dermatitis herpetiformis patients

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

Sulfones and sulfonamides in dermatology today

1 reference

https://api.crossref.org/works/10.1016%2FS0049-0172%2896%2980004-7

7 January 2021

10.1016/S0049-0172(96)80004-7

Identifiers

DOI

1 reference

26 September 2017

1 reference